Related Experiment Video
Updated: Oct 8, 2025

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
Published on: March 30, 2020
Future of anti-VEGF: biosimilars and biobetters
Monika Kapur1, Suvansh Nirula2, Mayuresh P Naik3
1Department of Ophthalmology, H.I.M.S.R. & H.A.H.C. Hospital, Hamdard University, Room No.3 of Eye OPD, First Floor of New OPD Building, H.A.H.C. Hospital, near GK-2, Alaknanda, Delhi, 110062, New Delhi, India. monikadkapur@gmail.com.
Abstract:
The advent of Anti- VEGFs like Lucentis (Ranibizumab), Eylea (Aflibercept) and off-label Avastin (Bevacizumab) have radically improved visual outcomes in patients of neovascular Age Related Macular Degeneration (nARMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). It is a matter of great concern that the US patents for Ranibizumab and Aflibercept expired in 2020 with European patents to expire in 2022 and 2025, respectively. With the expiry of these biologics, Biosimilars can prove to be saviours in the posterior segment pharmacotherapy owing to their cost effectiveness and availability of various options. Numerous biosimilars are expected to gain approval for clinical use from the US-FDA and EMA soon. Biobetters are better than the original biologic in one or more parameters but require more research and development resources. With the emergence of better manufacturing and purification processes it is imperative that the biologics and biosimilars become better. The Ophthalmologists need to have in depth knowledge about these Biosimilars and Biobetters before these molecules take over the mainstream market.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Microorganisms in Medicine and Therapeutics
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Bioequivalence: Overview
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

